Could a common antioxidant save newborns from deadly sepsis?

NCT ID NCT07380347

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding N-acetylcysteine (NAC) to standard care helps newborns with sepsis. Sepsis causes dangerous inflammation and cell damage. NAC may reduce this damage by boosting the body's defenses. The trial will enroll 50 near-term and term infants to see if NAC improves organ function, lowers hospital stay, and reduces death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.